Alaunos Therapeutics Beheer

Beheer criteriumcontroles 3/4

De CEO Alaunos Therapeutics is Dale Hogue, benoemd in Jan2024, heeft een ambtstermijn van minder dan een jaar. bezit rechtstreeks 0.25% van de aandelen van het bedrijf, ter waarde $ 8.16K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3 jaar en 3.9 jaar.

Belangrijke informatie

Dale Hogue

Algemeen directeur

US$11.1k

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	3yrs
Gemiddelde ambtstermijn bestuur	3.9yrs

Recente managementupdates

Recent updates

Ziopharm: Waiting On FYE 2021 For Further Clinical Data On TCR-T/CAR-T Therapies

Jun 19

ZIOPHARM records sharpest gain in nearly four months

Jun 09

Will ZIOPHARM Oncology (NASDAQ:ZIOP) Spend Its Cash Wisely?

May 11

ZIOPHARM Oncology, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

How Much Of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Do Institutions Own?

Mar 09

We're Hopeful That ZIOPHARM Oncology (NASDAQ:ZIOP) Will Use Its Cash Wisely

Jan 15

ZioPharm highlights upcoming catalysts, says current cash runway into mid-2022

Jan 14

Ziopharm Oncology to test non-viral CAR-T in leukemia and lymphoma patients

Dec 21

Activist holder wins Ziopharm Oncology board seats

Dec 17

Ziopharm Oncology CFO to step down

Dec 14

What Is The Ownership Structure Like For ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)?

Nov 23

Ziopharm says WaterMill’s nominees lack experience, White Rock backs proposal on board reconstitution

Nov 20

ZIOPHARM Oncology, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 06

Ziopharm Oncology thumbs down on investor's call for board seats

Nov 02

CEO

Dale Hogue (54 yo)

less than a year

Tenure

US$11,090

Compensatie

Mr. Dale Curtis Hogue, Jr. is Director of Alaunos Therapeutics, Inc. from December 29, 2023 and also serves as Interim Chief Executive Officer from January 20, 2024. Mr. Hogue has worked in various roles...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Dale Hogue	Interim CEO & Director	less than a year	US$11.09k	0.25% $ 8.2k
Melinda Lackey	Senior VP of Legal	3yrs	US$701.74k	0% $ 0
Michael Wong	Vice President of Finance & Principal Accounting Officer	3.2yrs	geen gegevens	geen gegevens

3.0yrs

Gemiddelde duur

47yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van TCRT wordt beschouwd als ervaren (gemiddelde ambtstermijn 3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Dale Hogue	Interim CEO & Director	less than a year	US$11.09k	0.25% $ 8.2k
Holger Weis	Independent Chairman of the Board	3.9yrs	US$900.26k	0.076% $ 2.5k
Carl June	Chairman of Scientific Advisory Board	4.4yrs	geen gegevens	geen gegevens
Jaime Vieser	Independent Director	3.9yrs	US$103.26k	0.97% $ 31.6k
Matthew Porteus	Member of Scientific Advisory Board	4.2yrs	geen gegevens	geen gegevens
Kole Roybal	Member of Scientific Advisory Board	4.2yrs	geen gegevens	geen gegevens
Robert Hofmeister	Independent Director	1.7yrs	US$84.01k	0% $ 0
Robert Postma	Independent Director	3.8yrs	US$104.26k	0.52% $ 16.9k
Steven Feldman	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

3.9yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van TCRT wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).

Alaunos Therapeutics Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Alaunos Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Alaunos Therapeutics, Inc. Appoints Dale Curtis Hogue, Jr. as Interim Chief Executive Officer

Alaunos Therapeutics, Inc. Appoints Dale Curtis Hogue as Director

Alaunos Therapeutics, Inc. Announces the Resignation of Mary Thistle as Member of the Board of Directors

Independent Director recently bought US$813k worth of stock

High number of new and inexperienced directors

Recent updates

Alaunos Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Alaunos Therapeutics, Inc. Appoints Dale Curtis Hogue, Jr. as Interim Chief Executive Officer

Alaunos Therapeutics, Inc. Appoints Dale Curtis Hogue as Director

Alaunos Therapeutics, Inc. Announces the Resignation of Mary Thistle as Member of the Board of Directors

Alaunos Therapeutics Receives a Staff Delisting Determination Letter from the Listing Qualifications Department

Nasdaq Approves Transfer of the Listing of the Common Stock of Alaunos Therapeutics from the Nasdaq Global Select Market to the Nasdaq Capital Market

Alaunos Therapeutics Announces Presentation At the 2Nd Hawaii Global Summit on Thoracic Malignancies

Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting

Alaunos Therapeutics, Inc. to Report Q1, 2023 Results on May 10, 2023

Forecast to breakeven in 2025

Price target decreased to US$3.75

Alaunos Therapeutics Receives A Deficiency Letter from Nasdaq Regarding Minimum Bid Price Requirement

Independent Director recently bought US$813k worth of stock

Alaunos Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $15 million.

Alaunos Therapeutics, Inc. has completed a Follow-on Equity Offering.

High number of new and inexperienced directors

Health Check: How Prudently Does Alaunos Therapeutics (NASDAQ:TCRT) Use Debt?

Alaunos Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Alaunos wins bullish view at Wells Fargo on promise of cell therapy technology

Alaunos Therapeutics, Inc. Highlights Data from TCR-T Library Phase 1/2 Trial at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference

Alaunos posts 51% tumor reduction for lung cancer therapy

Alaunos sheds 52% ahead of data readout for T-cell therapy platform

Alaunos Therapeutics Announces Early Clinical Data Showing Objective Clinical Response Using Its TCR-T Cell Therapy

Price target increased to US$4.20

Alaunos Therapeutics: Keep An Eye On Upcoming TCR-T Solid Tumor Study Data

Alaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference

Alaunos Therapeutics GAAP EPS of -$0.05 beats by $0.02

Alaunos Therapeutics, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Is Alaunos Therapeutics (NASDAQ:TCRT) Weighed On By Its Debt Load?

Price target decreased to US$3.70

Alaunos Therapeutics, Inc. to Report Q1, 2022 Results on May 16, 2022

Alaunos Therapeutics, Inc. Doses First Patient in TCR-T Library Phase 1/2 trial for the Treatment of Patients with Solid Tumors

High number of new and inexperienced directors

Is Alaunos Therapeutics (NASDAQ:TCRT) Using Debt Sensibly?

ZIOPHARM Oncology, Inc.(NasdaqGS:TCRT) dropped from NASDAQ Composite Index

Consensus forecasts updated

Consensus forecasts updated

ZIOPHARM Oncology, Inc. Announces Operational Progress

Is ZIOPHARM Oncology (NASDAQ:ZIOP) A Risky Investment?

Price target decreased to US$4.60

High number of new directors

ZIOPHARM Oncology, Inc. announced delayed 10-Q filing

ZIOPHARM Oncology, Inc.(NasdaqGS:ZIOP) dropped from Russell 3000E Value Index

Ziopharm: Waiting On FYE 2021 For Further Clinical Data On TCR-T/CAR-T Therapies

ZIOPHARM records sharpest gain in nearly four months

Chief Legal Officer & Secretary has left the company

Price target decreased to US$5.08

Will ZIOPHARM Oncology (NASDAQ:ZIOP) Spend Its Cash Wisely?

Price target decreased to US$5.08

ZIOPHARM Oncology, Inc. 2021 Q1 - Results - Earnings Call Presentation

How Much Of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Do Institutions Own?

CEO & Director Laurence James Cooper has left the company

Ziopharm Oncology, Inc. Receives IND Clearance by the U.S. FDA for Its TCR-T Trial Utilizing Six "Hotspot" TCRs from Its Library

Ziopharm Oncology, Inc. Appoints Timothy Cunningham Interim Chief Financial Officer

ZIOPHARM Oncology, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Ziopharm Oncology, Inc. Announces Election of Robert Postma to Board of Directors

New 90-day high: US$4.24

Ziopharm Oncology Inc. Announces Executive Changes

We're Hopeful That ZIOPHARM Oncology (NASDAQ:ZIOP) Will Use Its Cash Wisely

ZioPharm highlights upcoming catalysts, says current cash runway into mid-2022

New 90-day high: US$3.16

CEO & Director notifies of intention to sell stock

Ziopharm Oncology Announces Clearance of Taiwan’s First IND of Non-viral CAR-T for the Treatment of Relapsed CD19+ Leukemias and Lymphomas

Ziopharm Oncology to test non-viral CAR-T in leukemia and lymphoma patients

ZIOPHARM Oncology, Inc. Announces Executive Changes

Activist holder wins Ziopharm Oncology board seats

Ziopharm Oncology, Inc. Announces Resignation of Satyavrat Shukla as CFO

New 90-day high: US$3.09

Ziopharm Oncology CFO to step down